|Articles|February 20, 2008

L-acetylcarnitine Improves ADHD in Fragile X Syndrome

Treatment with L-acetylcarnitine may be beneficial in improving hyperactivity and social behavior in boys with fragile X syndrome who have attention-deficit/hyperactivity disorder (ADHD), according to an article published online Feb. 19 in the American Journal of Medical Genetics.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

ByJoshua Fitch, Senior Editor

November 25th 2025

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

ByMorgan Ebert, Managing Editor

November 14th 2025

Neurodevelopmental disorder risks not increased by prenatal acetaminophen use

ByCeleste Krewson, Assistant Editor

November 14th 2025

Genetic testing reveals key CNVs in affected children

ByMorgan Ebert, Managing Editor

November 13th 2025

Preterm birth linked to reduced odds of high school graduation

ByCeleste Krewson, Assistant Editor

October 21st 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

L-acetylcarnitine Improves ADHD in Fragile X Syndrome

Newsletter

Related Content

Otsuka submits centanafadine NDA to FDA to treat ADHD in children, adolescents, adults

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

Neurodevelopmental disorder risks not increased by prenatal acetaminophen use

Genetic testing reveals key CNVs in affected children

Preterm birth linked to reduced odds of high school graduation

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia

Jonathan Flyer, MD, outlines strategies to boost pediatric lipid screenings

Parents weigh holiday traditions against COVID-19 risks, national poll shows

Thao Ly-Phan, MD, discusses how an integrated obesity care model can strengthen family engagement

Eye spy: A case of a corneal lesion in an 8-year-old girl